AstraZeneca plc (ADR) - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
AZN New York 2834 https://www.astrazeneca.com/Home

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AstraZeneca plc (ADR)

AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod - Jun 20th, 2019 7:18 am
Ironwood's Linzess Lowers Abdominal Symptoms in IBS-C Patients - Jun 19th, 2019 3:21 pm
How AstraZeneca Is Advancing Its Oncology Portfolio in 2019 - Jun 18th, 2019 7:00 am
AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use - Jun 18th, 2019 6:59 am
AstraZeneca’s Lynparza Continues to Dominate - Jun 18th, 2019 5:30 am
AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment - Jun 18th, 2019 1:05 am
UPDATE 1-AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment - Jun 18th, 2019 1:02 am
Tagrisso: AstraZeneca’s Top-Selling Drug in Q1 - Jun 17th, 2019 2:30 pm
How Are AstraZeneca’s Revenues Trending in 2019? - Jun 17th, 2019 1:00 pm
What Analysts Recommend for Merck and AstraZeneca in June - Jun 17th, 2019 11:27 am
AstraZeneca Gives Detailed Data From Calquence Leukemia Study - Jun 17th, 2019 7:51 am
CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia - Jun 15th, 2019 5:00 am
Is AstraZeneca plc (AZN) A Good Stock To Buy? - Jun 14th, 2019 4:00 pm
Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod - Jun 14th, 2019 6:42 am
LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis - Jun 14th, 2019 5:00 am
Keytruda & 4 Other Reasons to Invest in Merck's (MRK) Stock - Jun 13th, 2019 7:31 am
The Zacks Analyst Blog Highlights: Bristol Myers, Merck, Roche, Lilly and AstraZeneca - Jun 10th, 2019 7:57 am
FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes - Jun 10th, 2019 6:00 am
New Sanofi CEO 2019: 8 Things to Know About Paul Hudson - Jun 7th, 2019 9:53 am
AstraZeneca's Calquence Meets Endpoint in 2nd CLL Study - Jun 7th, 2019 9:04 am